Biodesix, Inc.
NASDAQ Global MarketTotal Valuation
Biodesix, Inc. carries a market capitalization of 215.51M, placing it among publicly traded companies globally. Its enterprise value stands at 279.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 215.51M |
| Enterprise Value | 279.70M |
Share Statistics
Biodesix, Inc. currently has 10.55M shares outstanding.
| Shares Outstanding | 10.55M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.95, and the price-to-book ratio stands at 26.02.
| PE Ratio | N/A |
| PS Ratio | 1.95 |
| PB Ratio | 26.02 |
| P/TBV Ratio | -26.83 |
| P/FCF Ratio | -10.39 |
| P/OCF Ratio | -10.10 |
Enterprise Valuation
| EV / Sales | 2.72 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Biodesix, Inc. maintains a current ratio of 2.85, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 785.17, indicating elevated leverage, while an interest coverage ratio of -1.85 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.85 |
| Quick Ratio | 2.56 |
| Debt / Equity | 785.17 |
| Debt / EBITDA | -4.80 |
| Interest Coverage | -1.85 |
Financial Efficiency
| Return on Equity (ROE) | -540.01 |
| Return on Assets (ROA) | -30.33 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Biodesix, Inc.'s stock has gained approximately 213.68483% over the past 52 weeks. The 50-day moving average sits at 23.03, while the 200-day moving average is 14.79.
| Beta (5Y) | N/A |
| 52-Week Price Change | 213.68483% |
| 50-Day Moving Average | 23.03 |
| 200-Day Moving Average | 14.79 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Biodesix, Inc. generated 102.94M in revenue and converted that into -27.76M in net income, yielding earnings per share of -3.13. EBITDA reached -14.97M, while operating income came in at -20.58M.
| Revenue | 102.94M |
| Gross Profit | 84.93M |
| Operating Income | -20.58M |
| Pretax Income | -27.76M |
| Net Income | -27.76M |
| EBITDA | -14.97M |
| EBIT | -20.58M |
| Earnings Per Share (EPS) | -3.13 |
Balance Sheet
Biodesix, Inc. holds 30.00M in cash and equivalents against 71.80M in total debt, resulting in a net debt position of 16.82M. Total book value stands at 9.14M, with working capital of 28.27M providing operational flexibility.
| Cash & Cash Equivalents | 30.00M |
| Total Debt | 71.80M |
| Net Debt | 16.82M |
| Equity (Book Value) | 9.14M |
| Book Value Per Share | 0.87 |
| Working Capital | 28.27M |
Cash Flow
Biodesix, Inc. produced -19.83M in operating cash flow over the past twelve months. After subtracting -569,000.00 in capital expenditures, free cash flow totaled -20.40M - equivalent to -2.30 per share.
| Operating Cash Flow | -19.83M |
| Capital Expenditures | -569,000.00 |
| Free Cash Flow | -20.40M |
| FCF Per Share | -2.30 |
Margins
Biodesix, Inc. operates with a gross margin of 82.50, reflecting its pricing power and cost economics. The operating margin of -19.99 and net profit margin of -26.97 provide insight into operational efficiency.
| Gross Margin | 82.50 |
| Operating Margin | -19.99 |
| Pretax Margin | -26.97 |
| Profit Margin | -26.97 |
| EBITDA Margin | -14.54 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -12.47 |
| FCF Yield | -9.62 |
Stock Splits
Biodesix, Inc.'s most recent stock split took place on September 15, 2025 with a 20:1 split ratio.
| Last Split Date | 9/15/2025 |
| Split Ratio | 20:1 |
Scores
Biodesix, Inc. posts an Altman Z-Score of -6.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6.74 |